4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects


Por: Caudevilla-Galligo, F, Riba, J, Ventura, M, Gonzalez, D, Farre, M, Barbanoj, MJ, Bouso, JC

Publicada: 1 jul 2012
Resumen:
4-Bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive analogue of mescaline that is becoming increasingly popular as a rave and club drug. We investigated its presence in the illicit drug market in Spain, its pattern of use and profile of subjective effects. Drug material was analysed for 2C-B and information on pattern of use and subjective effects was obtained from recreational users. Scores were statistically compared with previously collected data on psychostimulants (d-amphetamine), entactogens (MDMA) and psychedelics (ayahuasca and Salvia divinorum). The percentage of samples containing 2C-B doubled between 2006 and 2009, evolved from powder to tablet form and showed low falsification rates. Respondents reported taking 2C-B orally in doses of about 20 mg. Subjective effects involved perceptual modifications analogous to those observed after ayahuasca and salvia but absent after amphetamine and MDMA. Pleasure and sociability effects did not differ from those after MDMA and incapacitation was lower than for the psychedelics used as comparators. In conclusion, we found 2C-B is consistently present in the illicit drug market in Spain. While it elicits perceptual modifications that are analogous to other psychedelics, the lower impairment and higher pleasurable effects make it comparable with entactogens.

Filiaciones:
Caudevilla-Galligo, F:
 Ctr Salud Puerta Bonita I, Madrid, Spain

 Grp Intervenc Drogas Soc Espanola Med Familiar &, Barcelona, Spain

Riba, J:
 Human Expt Neuropsychopharmacol, Barcelona, Spain

 Hosp Santa Creu & Sant Pau, Serv Farmacol Clin, Ctr Invest Medicaments, Barcelona, Spain

 Univ Autonoma Barcelona, Dept Farmacol Terapeut & Toxicol, Barcelona, Spain

 CIBERSAM, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain

Ventura, M:
 Asociac Bienestar & Desarrollo, Barcelona, Spain

Gonzalez, D:
 Inst Recerca Hosp Mar IMIM, Barcelona, Spain

 Univ Autonoma Barcelona, Dept Farmacol Terapeut & Toxicol, E-08193 Barcelona, Spain

Farre, M:
 Inst Recerca Hosp Mar IMIM, Barcelona, Spain

 Univ Autonoma Barcelona, Dept Farmacol Terapeut & Toxicol, E-08193 Barcelona, Spain

Barbanoj, MJ:
 Hosp Santa Creu & Sant Pau, Serv Farmacol Clin, Ctr Invest Medicaments, Barcelona, Spain

 Univ Autonoma Barcelona, Dept Farmacol Terapeut & Toxicol, Barcelona, Spain

 CIBERSAM, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain

Bouso, JC:
 Human Expt Neuropsychopharmacol, Barcelona, Spain

 Hosp Santa Creu & Sant Pau, Serv Farmacol Clin, Ctr Invest Medicaments, Barcelona, Spain

 Univ Autonoma Barcelona, Dept Farmacol Terapeut & Toxicol, Barcelona, Spain

 CIBERSAM, Ctr Invest Biomed Red Salud Mental, Barcelona, Spain
ISSN: 02698811





JOURNAL OF PSYCHOPHARMACOLOGY
Editorial
SAGE PUBLICATIONS LTD, 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 26 Número: 7
Páginas: 1026-1035
WOS Id: 000305625900010
ID de PubMed: 22234927

MÉTRICAS